Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 155

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 155
---
:|:--|:----|:-----|--------------------------:|:--|:----|:-----|--------:|:--|
| Net cash used in operating activities                                 |     | $    |                 (53,052 | ) |     | $    | (12,094 | ) |     | $    |                   (13,732 | ) |     | $    | (25,350 | ) |
| Net cash provided by (used in) investing activities                   |     |      |                  23,234 |   |     |      | (28,010 | ) |     |      |                     4,989 |   |     |      | (19,178 | ) |
| Net cash provided by financing activities                             |     |      |                  38,315 |   |     |      |  33,679 |   |     |      |                         — |   |     |      |  38,295 |   |
| Net increase (decrease) in cash, cash equivalents and restricted cash |     | $    |                   8,497 |   |     | $    |  (6,425 | ) |     | $    |                    (8,743 | ) |     | $    |  (6,233 | ) |

Operating Activities Cash used in operating activities for the six months ended June 30, 2025 was $13.7 million, consisting of net loss of $10.2 million adjusted for non-cash items, including $0.6 million related to gain from the change in the fair value of the warrant liabilities, partially offset by a $1.0 million charge for stock-based compensation expense. Additionally, we had outflows of $4.0 million due to a change in our net operating assets and liabilities from the year ended December 31, 2024, including a $4.4 million decrease in accounts payable and accrued expense primarily related to timing of payments and clinical trial expenses, partially offset by a $0.3 million decrease in prepaid expenses primarily related to decreased payments to our CRO due to the completion of the Phase 2 acute schizophrenia trial. Cash used in operating activities for the six months ended June 30, 2024 was $25.4 million, consisting of net loss of $43.9 million partially offset by non-cash items, including (i) the change in fair value of the warrant liabilities of $1.8 million, (ii) stock-based